Liver Transplant Rejection
📧 Sign up to get email alerts when something new happens for Liver Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Parenteral Ascorbic Acid Repletion in TransplantatIon [Phase 4]
The Phase 4 trial evaluating parenteral ascorbic acid repletion in liver transplantation has been suspended.
-
FDA approval · 2026-03-18FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for mycophenolate mofetil from Aurobindo Pharma Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients [Phase 1, Phase 2]
Phase 1/2 data on QEL-001 in A2-mismatch liver transplant patients show safety and preliminary clinical activity in the setting of transplan…
-
FDA approval · 2026-02-23FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's supplemental application for Mycophenolate mofetil (generic) under the ANDA, approving chan…
-
FDA approval · 2026-01-21FDA Approved: CYCLOSPORINE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's original ANDA for generic cyclosporine.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Prospective Study of White Blood Cells
This clinical trial update from Quell Therapeutics Limited describes a prospective study of white blood cells for autoimmune diseases, infla…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Clinical trial NCT06153641 investigates cytokeratin 18 as a non-invasive biomarker for liver transplant rejection; the study is currently ac…
-
FDA approval · 2025-10-17FDA Approved: TACROLIMUS — Supplemental Application (NORTHSTAR RX LLC)
The FDA approved a supplemental application for tacrolimus (generic) submitted by NORTHSTAR RX LLC.
-
FDA approval · 2025-09-26FDA Approved: TACROLIMUS — Supplemental Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s supplemental application for tacrolimus, updating labeling to support its use in preventing organ transpla…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection [Phase 1, Phase 2]
This clinical trial update describes an investigation into CRISPR-edited HLA donor livers to reduce transplant rejection, with Phase 1 and P…
-
FDA approval · 2025-06-27FDA Approved: MYHIBBIN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
FDA approved a supplemental application for MYHIBBIN (mycophenolate mofetil) submitted by Azurity Pharmaceuticals, Inc. The supplement perta…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Global Utilization And Registry Database for Improved preservAtion of doNor Livers
This clinical trial update describes a global registry/database aimed at improving preservation of donor livers and is currently enrolling b…
-
FDA approval · 2025-02-12FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for mycophenolate mofetil from Strides Pharma Science Limited.
-
FDA approval · 2025-02-12FDA Approved: TACROLIMUS — Original Application (Nexus Pharmaceuticals, LLC)
Generic tacrolimus from Nexus Pharmaceuticals has been approved through an original ANDA for use in preventing organ transplant rejection.
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients [Phase 4]
A Phase 4 clinical trial update describes converting maintenance tacrolimus from Prograf to Envarsus in liver transplant recipients, with en…
-
FDA approval · 2024-11-07FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Wuxi Fortune Pharmaceutical Co.,Ltd.)
The FDA approved the original application for a generic mycophenolate mofetil formulation from Wuxi Fortune Pharmaceutical Co., Ltd.
-
FDA approval · 2024-10-22FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' original application for a generic mycophenolate mofetil product.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare's supplemental application for generic Mycophenolate mofetil. The approval supports continued use for prevent…
-
FDA label_change · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for Mycophenolate mofetil from Endo USA, Inc., updating the drug's labeling.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Mycophenolate mofetil from Aurobindo Pharma Limited, allowing the generic product for use in pre…
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CellCept (mycophenolate mofetil hydrochloride) submitted by Genentech to update the label.
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CellCept (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for Mycophenolate mofetil from Meitheal Pharmaceuticals Inc., confirming the generic product's appro…
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved Genentech's supplemental application for CELLCEPT (mycophenolate mofetil), resulting in an approved update to the product label…
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Lannett Company, authorizing a generic version under ANDA 214525.